Assistant Professor of Pediatrics, University of Pennsylvania School of Medicine
- Department: Pediatrics
- Division: Oncology
- Primary Address:
The Children's Hospital of Philadelphia
Division of Oncology, 4028 CTRB
3501 Civic Center Boulevard
Philadelphia, PA 19104
Pediatric Neuro-Oncology and Early Phase Clinic Trials/Developmental Therapeutics in Pediatric Brain Tumors. Particular interest in intratumoral hypoxia as a therapeutic target, a marker of treatment resistance, and a biomarker exploitable for non-invasive tumor imaging.
Signal transduction in embryonal tumors of the developing nervous system. Translating aberrantly expressed/activated neurodevelopmental signaling mechanisms into potential therapeutic targets
Signal transduction in embryonal tumors of the nervous system.
- Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia (2006 – present)
- Ph.D., Neurobiology, Yale University (1996)
- M.D., Medicine, Yale University School of Medicine (1996)
- M.Phil., Neurobiology, Yale University (1993)
- B.S., Psychobiology, Univeristy of Southern California (1986)
I'm part of a small group that focuses specifically on brain tumors. Our multidisciplinary team includes oncologists, a neurologist, neurosurgeons, a radiation oncologist, social workers and a neuropsychologist, along with skilled nurse practitioners. This is the broad spectrum of expertise that The Children's Hospital of Philadelphia brings to treating its patients with brain tumors.
Treating cancer is a team effort at Children's Hospital, and we consider patients and their families a part of the team. Since our young patients are dependent on their parents for medical decision making, I try to give them a sense of some control over their disease, communicating in an age appropriate manner. Kids do much better, even when facing death, when they are part of the treatment plan and "secrets" are not kept from them.
I do both basic science and clinical research that focuses on developmental therapeutics in tumors of the nervous system. In particular I and my colleagues are looking at signal transduction in neuroblastoma and medulloblastoma. We are evaluating the biological effects of neurotrophin receptor expression on the growth properties of these tumors. Neurotrophins are able to signal certain cells to survive, mature or grow. The Trk family of neurotrophin receptors plays a critical role in these diverse behaviors.
We recently completed a clinical trial that targeted these receptors to inhibit signaling in neuroblastoma. The results are promising that this could be a therapeutic target for high risk neuroblastoma. We also are studying the way that Trk receptor molecules located on the surface of medulloblastoma cells regulate tumor growth and development. These studies may help to identify new therapeutic targets in the Trk signaling pathways.
As part of our approach to identifying new treatments for children with brain tumors, we are members of the multi-institutional Pediatric Brain Tumor Consortium (PBTC) and the Developmental Therapeutics Children's Oncology Group. These groups are involved in early phase clinical trials for relapsing and refractory brain tumors, with a particular focus on testing new, targeted treatments in children with brain tumors.
Our Children's Hospital team has partnered with drug development groups, and we are rapidly identifying drugs that show promise in patients with brain tumors who have no other curable option. There is a sense of urgency in our group -- we don't randomly test drugs but work collaboratively with laboratory scientists and drug development companies on rational, biologically-based targets. The best example of this is a drug for medulloblastoma that was recently rapidly brought to a PBTC clinical trial.
There is huge progress in getting promising drugs to kids with cancer. Through our cooperative group consortia, the pace is much more rapid than in past years, and Children's Hospital is a major part of the effort to help bring new agents to children with brain tumors.
- Sontheimer H., Minturn JE., Black JA., Waxman SG., Ransom BR.. Specificity of cell-cell coupling in rat optic nerve astrocytes in vitro. Proceedings of the National Academy of Sciences of the United States of America. Vol 87(24) . 1990 Dec:9833-7.
- Minturn JE., Black JA., Angelides KJ., Waxman SG.. Sodium channel expression detected with antibody 7493 in A2B5+ and A2B5- astrocytes from rat optic nerve in vitro. GLIA. Vol 3(5) . 1990:358-67.
- Sontheimer H., Minturn JE., Black JA., Ransom BR., Waxman SG.. Two types of Na(+)-currents in cultured rat optic nerve astrocytes: changes with time in culture and with age of culture derivation. Journal of Neuroscience Research. Vol 30(2) . 1991 Oct:275-87.
- Sontheimer H., Minturn JE., Ransom BR., Black JA., Cornell-Bell AH., Waxman SG.. Cell coupling is restricted to subpopulations of astrocytes cultured from rat hippocampus and optic nerve. Annals of the New York Academy of Sciences. Vol 633. 1991:592-6.
- Minturn JE., Sontheimer H., Black JA., Angelides KJ., Ransom BR., Ritchie JM., Waxman SG.. Membrane-associated sodium channels and cytoplasmic precursors in glial cells. Immunocytochemical, electrophysiological, and pharmacological studies.[see comment]. [Review] [35 refs]. Annals of the New York Academy of Sciences. Vol 633. 1991:255-71.
- Black JA., Sontheimer H., Minturn JE., Ransom BR., Waxman SG.. The expression of sodium channels in astrocytes in situ and in vitro. [Review] [31 refs]. Progress in Brain Research. Vol 94. 1992:89-107.
- Minturn JE., Sontheimer H., Black JA., Ransom BR., Waxman SG.. Sodium channel expression in optic nerve astrocytes chronically deprived of axonal contact. GLIA. Vol 6(1) . 1992:19-29.
- Waxman SG., Sontheimer H., Black JA., Minturn JE., Ransom BR.. Dynamic aspects of sodium channel expression in astrocytes. [Review] [68 refs]. Advances in Neurology. Vol 59. 1993:135-55.
- Minturn JE., Fryer HJ., Geschwind DH., Hockfield S.. TOAD-64, a gene expressed early in neuronal differentiation in the rat, is related to unc-33, a C. elegans gene involved in axon outgrowth. Journal of Neuroscience. Vol 15(10) . 1995 Oct:6757-66.
- Black JA., Westenbroek R., Minturn JE., Ransom BR., Catterall WA., Waxman SG.. Isoform-specific expression of sodium channels in astrocytes in vitro: immunocytochemical observations. GLIA. Vol 14(2) . 1995 Jun:133-44.
- Minturn JE., Geschwind DH., Fryer HJ., Hockfield S.. Early postmitotic neurons transiently express TOAD-64, a neural specific protein. Journal of Comparative Neurology. Vol 355(3) . 1995 May 8:369-79.
- Ho R., Eggert A., Hishiki T., Minturn JE., Ikegaki N., Foster P., Camoratto AM., Evans AE., Brodeur GM.. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Research. Vol 62(22) . 2002 Nov 15:6462-6.
- Minturn JE and Kelly KM. Aplastic Anemia.. The 5-Minute Pediatric Consult, 3rd Edition. Lippincott Williams & Wilkins, Philadelphia, PA; 2002:130-131.
- Minturn JE and Kelly KM. Hemophilia. The 5-Minute Pediatric Consult, 3rd Edition. Lippincott Williams & Wilkins, Philadelphia, PA.; 2002:420-421.
- Minturn JE. Idiopathic Thrombocytopenic Purpura. The 5-Minute Pediatric Consult, 3rd Edition. Lippincott Williams & Wilkins, Philadelphia, PA; 2002:464-465.
- Minturn JE and Friedman DL. Teratoma. The 5-Minute Pediatric Consult, 3rd Edition. Lippincott Williams & Wilkins, Philadelphia, PA; 2002:812-813.
- Ho R, Minturn JE, Evans AE, and Brodeur GM.. Epithelial growth factor receptor (EGFR) inhibitor ZD1839 potently inhibits the growth of neuroblastomas.. Proc Am Soc Clin Oncol. Vol 22(807) . 2003.
- Minturn JE, Ho R, Rappaport E, Evans AE, and Brodeur GM.. Gene expression patterns in neuroblastoma cells mediated by TrkA and TrkB expression and activation.. Advances in Neuroblastoma Research. 2004 June 16-20.
- Ho R, Minturn JE, Qi X, Evans AE, and Brodeur GM.. Epidermal growth factor receptor mediated survival of human neuroblastomas.. Advances in Neuroblastoma Research. 2004 June 16-20.
- Ho R, Minturn JE, Simpson A, Qi X, Evans A, and Brodeur GM.. Differential effect of P75 coexpression on TrkA and TrkB response to ligand in neuroblastoma.. American Association for Cancer Research Proceedings. Vol 46(2928) . 2005 April 16-20.
- Maris JM, Minturn JE, Evans, AE, Brophy P, Matthay KK, Hellriegel E, Brown P, and Brodeur GM.. Phase I Trial of the orally bioavailable Trk tyrosine kinase inhibitor CEP-701 in refractory neuroblastoma: a New Approaches to Neuroblastoma Therapy (NANT) Study.. SIOP 37th Annual Meeting Abstract. (734) . 2005 September 21-24.
- Evans AE, Qi X, Ho R, Minturn JE, and Brodeur GM.. Selective inhibition of TrkB activation by tyrosine kinase inhibitor CEP-701 shows biological activity in pre-clinical models of neuroblastoma.. Proceedings from the AACR-NCI-EORTC International Conference of Molecular Targets and Cancer Therapeutics. (B47) . 2005 November 14-18.
- Ho R., Minturn JE., Hishiki T., Zhao H., Wang Q., Cnaan A., Maris J., Evans AE., Brodeur GM.. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Research. Vol 65(21) . 2005 Nov 1:9868-75.
- Eslin D and Minturn JE. Teratoma. The 5-Minute Pediatric Consult, 4th Edition. Lippincott Williams & Wilkins, Philadelphia, PA; 2005.
- Jane E. Minturn, Anisha M. Simpson, Ruth Ho, Jennifer E. Light, Audrey E. Evans, Garrett M. Brodeur. P75 Neurotrophin Receptor Expression and Signaling in Neuroblastoma. Advanced in Neuroblastom Research. Vol 12. 2006 May:68.
- R. Ho, JE Minturn, A Simpson, X Qi, N Cordella, AE Evans, GM Brodeur. The Effect of P75 on Trk Receptors in Neuroblastoma. Advances in Neuroblastoma Research. Vol 12. 2006 May:69.
- Anisha M. Simpson, Jane E. Minturn, Ruth Ho, Eli A. Gordin, Jennifer W. Cheng,, Huaqing Zhao, Garrett M. Brodeur. Significance of TrkAIII Isoform Expression in Human Neuroblastoma. Advances in Neuroblastoma Research. Vol 12. 2006 May:75.
- Gordin EA, Ho R, Minturn JE, Simpson AM, Evans AE, Zhao H, London WB, Maris JM, Brodeur GM. Clinical significance of Trk family gene expression in human neuroblastomas. Advances in Neuroblastoma Research. Vol 12. 2006 May:86.
- Evans AE, Qi X, Ho R, Minturn JE, Barr R, Cartright J, Miknyoczki S, Maris JM, Brodeur GM.. The Trk-selective tyrosine kinase inhibitor CEP-701 shows biological activity alone and with chemotherapy in pre-clinical models of neuroblastoma. Advances in Neuroblastoma Research. Vol 12. 2006 May:90.
- Maris JM, Minturn JE, Evans AE, Brophy P, Matthay KK, Brown P, Hellriegel E, Brodeur GM. Phase 1 trial of the orally bioavailable Trk tyrosine kinase inhibitor CEP-701 in refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study. Advances in Neuroblastoma Research. Vol 12. 2006 May:125.
- Minturn JE, Light JE, Phillips P, Brodeur GM. Translating tumor cell line data into rational clinical trial design: recognizing the limitations of studying pediatric brain tumors in vitro.. American Cancer Society Career Development Conference for Beginning Investigators in Applied and Clinical Research. 2007 November.
- Balamuth NJ, Courtright JP, Barr R, Cole K, Wood A, Minturn J, Evans AE, Miknyoczki S, Brodeur GM, Maris JM. Dual VEGF and Trk signaling inhibition is an effective strategy in preclinical models of neuroblastoma. American Society of Pediatric Hematology/Oncology. (1280) . 2008 May.
- Minturn JE, Light J, Brodeur GM. Trk receptor expression and neurotrophin-mediated signaling in medulloblastoma. American Society of Pediatric Hematology/Oncology. (1532) . 2008 May.
- Ho R, Minturn JE, Simpson A, Light J, Iyer R, Zhao H, Evans AE, Brodeur GM. Receptor tyrosine kinase (RTK) inhibition of human neuroblastomas.. Advances in Neuroblastoma Research. Vol 13. 2008 May.
- Minturn JE, Ho R, Light J, Varela C, Iyer R, Simpson A, Zhao H, Evans AE, Brodeur GM. Differences between TrkA vs. TrkB-mediated signal transduction and inhbition in neuroblastoma. Advances in Neuroblastoma Research. Vol 13. 2008 May.
- Simpson A, Minturn JE, Ho R, Light J, Iyer R, Zhao H, Evans AE, Brodeur GM.. Significance of TrkA isoform expression in neuroblastomas. Advances in Neuroblastoma Research. Vol 13. 2008 May.
- Minturn JE. Teratoma. The 5-Minute Pediatric Consult, 5th Edition. Vol 5. Lippincott Williams & Wilkins; 2008:840-841.
- Fisher MJ, Minturn J, Phillips PC. Brain Tumors. Pediatric Hematology/Oncology: The Requisites in Pediatrics. Vol 1. Mosby Publishing; 2008.
- Ho R, Minturn JE, Simpson AM, Iyer R, Light JE, Evans AE, Brodeur GM. The effect of P75 on Trk receptors in neuroblastomas. Journal of Neuroscience Research. 2008.
- Russell-Swetek A, West AN, Minturn JE, Jenkins J, Rodriguez-Galindo C, Ribeiro R, Zambetti GP. Identification of a novel TP53 germline mutation E285V in a rare case of pediatric adrenocortical carcinoma and choroid plexus carcinoma. Journal of Medical Genetics. 2008.
- Wei Z, Minturn JE, Rappaport E, Brodeur G, Li H. Incorporation of genetic pathway information into analysis of multivariate gene expression data.. Biometrics. 2008.
- Brodeur Garrett M, Minturn Jane E, Ho Ruth, Simpson Anisha M, Iyer Radhika, Varela Carly R, Light Jennifer E, Kolla Venkatadri, Evans Audrey E. Trk receptor expression and inhibition in neuroblastomas.. Clinical cancer research : an official journal of the American Association for Cancer Research. Vol 15(10) . 2009 May:3244-50.
- Iyer Radhika, Evans Audrey E, Qi Xiaoxue, Ho Ruth, Minturn Jane E, Zhao Huaqing, Balamuth Naomi, Maris John M, Brodeur Garrett M. Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. Vol 16(5) . 2010 Mar:1478-85.